Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials?
about
Sublingual immunotherapy: World Allergy Organization position paper 2013 update.A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical AssoProspective validation of the "rhino conjunctivitis allergy-control-SCORE©" (RC-ACS©).The efficacy assessment of a self-administered immunotherapy protocolA review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia).Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil ActivationSubcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis.Standardization and Regulation of Allergen Products in the European Union.Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper.Novel approaches and perspectives in allergen immunotherapy.Sublingual immunotherapy in patients with latex allergy: systematic review and meta-analysis of randomized controlled trials.Comparison of six disease severity scores for allergic rhinitis against pollen counts a prospective analysis at population and individual level.Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy.House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients.Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.Comparison of scores associating symptoms and rescue medication use for evaluating the efficacy of allergy immunotherapy in seasonal allergic rhinoconjunctivitis: results from five trials.Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*
P2860
Q30440195-2AFD1971-98F5-4B2B-B738-1EC71FC00467Q34548671-5FC75EED-758E-40E3-A372-EF4938C10C89Q35777126-D8CD0E45-19E1-44CD-8DEB-6031E31F2828Q36376780-2E24C355-48DD-4310-AAA6-0F24487B6A20Q36881918-372C2E0A-D5A7-45BC-ADDE-2C3AACC6477CQ37652965-E2CC90D2-C7C5-476E-924A-9E3E042A0879Q37653676-4E0BB232-7706-4D62-9E9A-99AA2B08582EQ38025664-BDD4E426-DBCD-4C53-96F3-B0AE8759BF6DQ38206795-E0056165-A3F3-46B5-B066-244B2E65A3ACQ38207691-D1EA126C-B99E-4BD8-98F8-6A7635119CD8Q38732578-6AEB0180-2F7D-498D-997E-FA644E3EA0A4Q38745619-2D5E069F-9AF3-4A19-B2B6-428D0840FB70Q38792114-4F3A393D-CB3A-4E2A-9A56-1BDA5892ADFAQ39103046-0371755B-F028-4C38-94D7-5667F844FC82Q39188382-599F9EB3-7444-4568-A8F2-77B84C5F0A17Q39908406-4EFF71BE-9C61-4FC3-AED0-3BB769A716B8Q42153928-2AE3988D-1CFD-40F2-8A7E-67BC84313BE2Q45057152-69FCB06E-BDE1-48F9-A5A7-632CE9109AF5Q47437151-779BAA3A-9FB0-4A8B-A090-E09C5A19DB99Q48178552-3BBD057B-A542-4F46-9943-C02873C2ED9FQ53714415-AA7AE6B5-67C8-44D5-940A-51272F4004B8Q55669640-94CE2529-B06D-450F-83B7-C44185FBA795Q57384848-CB52D9E7-275E-4B90-8A79-1EFDDDB4A286
P2860
Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Allergen-specific immunotherap ...... in monitoring clinical trials?
@en
Allergen-specific immunotherap ...... in monitoring clinical trials?
@nl
type
label
Allergen-specific immunotherap ...... in monitoring clinical trials?
@en
Allergen-specific immunotherap ...... in monitoring clinical trials?
@nl
prefLabel
Allergen-specific immunotherap ...... in monitoring clinical trials?
@en
Allergen-specific immunotherap ...... in monitoring clinical trials?
@nl
P2093
P1476
Allergen-specific immunotherap ...... in monitoring clinical trials?
@en
P2093
P304
289-309, x
P356
10.1016/J.IAC.2011.02.004
P577
2011-05-01T00:00:00Z